Synchronous resection for colorectal liver metastases: The future.

03:42 EST 20th December 2014 | BioPortfolio

Summary of "Synchronous resection for colorectal liver metastases: The future."

Colorectal Cancer is a common malignancy. Many patients have metastatic disease at presentation and a significant proportion subsequently go onto develop metastatic disease, following surgery for the primary disease. Some groups advocate that synchronous metastatic disease should be resected at the same time as the primary, whereas others believe that outcomes are better following delayed resection for metastatic disease. The following review aims to outline the arguments in favour of both and to suggest some broad guidelines.


Department of General Surgery, University Hospital Aintree, United Kingdom.

Journal Details

This article was published in the following journal.

Name: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of
ISSN: 1532-2157


PubMed Articles [12737 Associated PubMed Articles listed on BioPortfolio]

Evaluation of the safety and efficacy of simultaneous resection of primary colorectal cancer and synchronous colorectal liver metastases.

It remains unclear whether primary colorectal cancer and synchronous liver metastases (SLMs) should be resected simultaneously or with a staged procedure.

Systematic review of surgical management of synchronous colorectal liver metastases.

The optimal management of colorectal cancer with synchronous liver metastases has not yet been elucidated. The aim of the present study was systematically to review current evidence concerning the tim...

Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases.

To evaluate the therapeutic efficacy of radiofrequency ablation (RFA) for resectable colorectal liver metastases (CRLM) compared with that of resection.

Retrospective analysis of clinical and pathologic risk factors in liver resection for hepatic colorectal metastases.

Objective: To analyze the clinical and pathologic risk factors of surgical treatment for liver metastases from colorectal cancer. Materials and Methods: The data on 98 patients who underwent liver res...

Cure Model Survival Analysis After Hepatic Resection for Colorectal Liver Metastases.

Statistical cure is achieved when a patient population has the same mortality as cancer-free individuals; however, data regarding the probability of cure after hepatectomy of colorectal liver metastas...

Clinical Trials [3441 Associated Clinical Trials listed on BioPortfolio]

Neo-Adjuvant Therapy and the Effect on Synchronous Metastatic Growth

Study Hypothesis • As well as in animal models as in patients with colorectal cancer resection of the primary tumor resulted in increase in vascular density, metabolism and secondary tu...

Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases

Hypothesis of the study: Neoadjuvant chemotherapy with Bevacizumab impairs postoperative outcome after resection of colorectal liver metastases.

Resection of Colorectal Liver Metastases With or Without Routine Hilar Lymphadenectomy

It is uncertain, whether hilar lymphadenectomy should be performed routinely in patients undergoing resection of colorectal liver metastases. For this reason it is the aim of the present ...

Quality of Life and Liver Metastases

An increasing aggressiveness in the surgical approach of colorectal liver metastases is observed. This seems only justified when, besides prolongation of survival, also the health status o...

Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers

More and more colorectal surgeons believe that surgical resections of hepatic metastases from colorectal cancer is the only chance for cure of patients. The five-year survival for patients...

Medical and Biotech [MESH] Definitions

Clusters of colonic crypts that appear different from the surrounding mucosa when visualized after staining. They are of interest as putative precursors to colorectal adenomas and potential biomarkers for colorectal carcinoma.

Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.

Tumor suppressor genes located in the 5q21 region on the long arm of human chromosome 5. The mutation of these genes is associated with the formation of colorectal cancer (MCC stands for mutated in colorectal cancer).

Tumor suppressor genes located in the 18q21-qter region of human chromosome 18. The absence of these genes is associated with the formation of colorectal cancer (DCC stands for deleted in colorectal cancer). The products of these genes show significant homology to neural cell adhesion molecules and other related cell surface glycoproteins.

Irradiation of one half or both halves of the body in the treatment of disseminated cancer or widespread metastases. It is used to treat diffuse metastases in one session as opposed to multiple fields over an extended period. The more frequent treatment modalities are upper hemibody irradiation (UHBI) or lower hemibody irradiation (LHBI). Less common is mid-body irradiation (MBI). In the treatment of both halves of the body sequentially, hemibody irradiation permits radiotherapy of the whole body with larger doses of radiation than could be accomplished with WHOLE-BODY IRRADIATION. It is sometimes called "systemic" hemibody irradiation with reference to its use in widespread cancer or metastases. (P. Rubin et al. Cancer, Vol 55, p2210, 1985)

Search BioPortfolio:

Relevant Topic

Latest News Clinical Trials Research Drugs Reports Corporate
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs.  Cancer sometimes begins in one part of the body before spre...